ECONOMIC AND HEALTH SERVICE IMPACT OF IMPROVED HEALING IN HARD-TO-HEAL DIABETIC FOOT ULCERS IN THE UNITED KINGDOM: A COST-CONSEQUENCE ANALYSIS
Author(s)
Derek O'Boyle, BA, MSc1, Leo M. Nherera, BSc, MSc, PhD2, Rebecca Decker, M.J.2.
1Convatec Inc, Dublin, Ireland, 2Convatec Inc, Bridgewater, NJ, USA.
1Convatec Inc, Dublin, Ireland, 2Convatec Inc, Bridgewater, NJ, USA.
OBJECTIVES: Hard-to-heal diabetic foot ulcers (DFUs) are associated with prolonged treatment, substantial healthcare resource utilisation, and considerable costs to the United Kingdom (UK) health services. A nitric oxide-generating medical device (EDX110) has been associated with improved healing outcomes compared with standard care in hard-to-heal DFUs. This study estimated the clinical and economic consequences of improved healing outcomes associated with EDX110 in UK health services.
METHODS: A deterministic cost-consequence model was developed from a UK health services perspective to estimate the consequences of improved healing over 24 weeks in a cohort of 100 hard-to-heal DFUs. Healing probabilities (49% versus 30% healed at 24 weeks) were informed by published evidence evaluating a nitric oxide-generating medical device compared with standard care. Model inputs included healthcare professional visits, dressing-related resource use, hospitalisations, amputations, and associated costs. Outcomes included ulcers healed, healthcare resource utilisation, cost per healed ulcer, and net economic consequences relative to standard care.
RESULTS: In the model, improved healing outcomes were estimated to result in 19 additional ulcers healed per 100 DFUs managed over 24 weeks. Total estimated cost savings were £173,940 per 100 DFUs managed, equivalent to £1,739 per ulcer. Improved healing was associated with an estimated £13,193 reduction in cost per healed ulcer. Compared with standard care, improved healing reduced healthcare utilisation by an estimated 555 healthcare professional visits and reduced staff time requirements by approximately 278 hours.
CONCLUSIONS: Improved healing in hard-to-heal DFUs may generate meaningful economic and resource-use benefits for UK health services. Cost-consequence analyses informed by published clinical evidence may support implementation decision-making by quantifying the potential impact of advanced wound management interventions on healing outcomes, healthcare utilisation, and costs.
METHODS: A deterministic cost-consequence model was developed from a UK health services perspective to estimate the consequences of improved healing over 24 weeks in a cohort of 100 hard-to-heal DFUs. Healing probabilities (49% versus 30% healed at 24 weeks) were informed by published evidence evaluating a nitric oxide-generating medical device compared with standard care. Model inputs included healthcare professional visits, dressing-related resource use, hospitalisations, amputations, and associated costs. Outcomes included ulcers healed, healthcare resource utilisation, cost per healed ulcer, and net economic consequences relative to standard care.
RESULTS: In the model, improved healing outcomes were estimated to result in 19 additional ulcers healed per 100 DFUs managed over 24 weeks. Total estimated cost savings were £173,940 per 100 DFUs managed, equivalent to £1,739 per ulcer. Improved healing was associated with an estimated £13,193 reduction in cost per healed ulcer. Compared with standard care, improved healing reduced healthcare utilisation by an estimated 555 healthcare professional visits and reduced staff time requirements by approximately 278 hours.
CONCLUSIONS: Improved healing in hard-to-heal DFUs may generate meaningful economic and resource-use benefits for UK health services. Cost-consequence analyses informed by published clinical evidence may support implementation decision-making by quantifying the potential impact of advanced wound management interventions on healing outcomes, healthcare utilisation, and costs.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
MT10
Topic
Clinical Outcomes, Economic Evaluation, Medical Technologies
Disease
Diabetes/Endocrine/Metabolic Disorders (including obesity)